Key facts
- It has raised $39.0M; the latest was IPO in Dec 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, YuanBio Venture Capital, Furong Capital, Huayi Capital, Jiading Venture Capital — 10 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Juncell Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Juncell Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juncell Therapeutics
Developer of tumor cell therapy intended to serve the medical industry. The company provides solutions to separate TILs(Ttumor Iinfiltrating Llymphocyte) from tumor tissues, develop them outside of the human body, and re-inject them back to treat tumors, enabling patients to fight tumors with fewer side effects.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 4
- Website
- juncell.com/
- Ownership
- In IPO Registration
Juncell Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juncell Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juncell Therapeutics in its N-PORT filings yet. We sweep new filings monthly.